Rodgers, A;
Salam, A;
Cushman, W;
de Silva, A;
Di Tanna, GL;
Gnanenthiran, SR;
Grobbee, D;
... Whelton, P; + view all
(2024)
Rationale for a New Low-Dose Triple Single Pill Combination for the Treatment of Hypertension.
Global heart
, 19
(1)
, Article 18. 10.5334/gh.1283.
Preview |
PDF
gh-19-1-1283.pdf - Published Version Download (2MB) | Preview |
Abstract
Two recent large trials showed the potential of single pill combinations (SPCs) with ≥3 low-dose components among people with hypertension who were untreated or receiving monotherapy. In both trials, these 'hypertension polypills' were superior to usual care, achieving >80% BP control without increasing withdrawal due to side effects. However, there are no such products available for prescribers. To address this unmet need, George Medicines developed GMRx2 with telmisartan/amlodipine/indapamide in three strengths (mg): 10/1.25/0.625, 20/2.5/1.25; 40/5/2.5. Two pivotal trials are ongoing to support FDA submission for the treatment of hypertension, including initial treatment. These assess efficacy and safety of GMRx2 compared to: placebo, and each of the three possible dual combinations. Regulatory submissions are planned for 2024, with the aim of providing access to GMRx2 in developed and developing regions. Wider implementation of GMRx2-based treatment strategies will be guided by further research to inform access and appropriate scale up.
| Type: | Article |
|---|---|
| Title: | Rationale for a New Low-Dose Triple Single Pill Combination for the Treatment of Hypertension |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.5334/gh.1283 |
| Publisher version: | http://dx.doi.org/10.5334/gh.1283 |
| Language: | English |
| Additional information: | © 2024 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 license (unless stated otherwise) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| Keywords: | blood pressure, fixed dose, hypertension, polypill, single pill combination, Humans, Antihypertensive Agents, Hypertension, Indapamide, Blood Pressure, Treatment Outcome |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science > Population Science and Experimental Medicine |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10188312 |
Archive Staff Only
 |
View Item |
